Key result
Transplanted embryonic stem cells overexpressing TIMP-1 significantly improved engraftment, cardiac myocyte differentiation, and heart function while reducing apoptosis and fibrosis (p<0.05) post-MI.
Why the study?
Does transplantation of ES cells overexpressing TIMP-1 improve cardiac remodeling and function in a mouse model of myocardial infarction?
Does transplantation of ES cells overexpressing TIMP-1 improve cardiac remodeling and function in a mouse model of myocardial infarction?
Transplantation of embryonic stem cells overexpressing TIMP-1 attenuates adverse myocardial remodeling and improves cardiac function in a mouse model of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for TIMP-1-engineered stem cells post-MI; leaves open human translation pending clinical trials.
Transplanted embryonic stem (ES) cells, following myocardial infarction (MI), contribute to limited cardiac repair and regeneration with improved function. Therefore, novel strategies are still needed to understand the effects of genetically modified transplanted stem cells on cardiac remodeling. The present study evaluates whether transplanted mouse ES cells overexpressing TIMP-1, an antiapoptotic and antifibrotic protein, can enhance cardiac myocyte differentiation, inhibit native cardiac myocyte apoptosis, reduce fibrosis, and improve cardiac function in the infarcted myocardium. MI was produced in C57BL/6 mice by coronary artery ligation. TIMP-1-ES cells, ES cells, or culture medium (control) were transplanted into the peri-infarct region of the heart. Immunofluorescence, TUNEL staining, caspase-3 activity, ELISAs, histology, and echocardiography were used to identify newly differentiated cardiac myocytes and assess apoptosis, fibrosis, and heart function. Two weeks post-MI, significantly (p < 0.05) enhanced engraftment and cardiac myocyte differentiation was observed in TIMP-1-ES cell-transplanted hearts compared with hearts transplanted with ES cells and control. Hearts transplanted with TIMP-1-ES cells demonstrated a reduction in apoptosis as well as an increase (p< 0.05) in p-Akt activity compared with ES cells or culture media controls. Infarct size and interstitial and vascular fibrosis were significantly (p< 0.05) decreased in the TIMP-1-ES cell group compared to controls. Furthermore, MMP-9, a key profibrotic protein, was significantly (p < 0.01) reduced following TIMP-1-ES cell transplantation. Echocardiography data showed fractional shortening and ejection fraction were significantly (p< 0.05) improved in the TIMP-1-ES cell group compared with respective controls. Our data suggest that transplanted ES cells overexpressing TIMP-1 attenuate adverse myocardial remodeling and improve cardiac function compared with ES cells that may have therapeutic potential in regenerative medicine.
No takes yet. Share an insight, caveat, or question.
Glass et al. (2012) studied Myocardial Infarction. Transplanted mouse embryonic stem cells overexpressing TIMP-1 vs. Embryonic stem cells or culture medium was evaluated on Engraftment, cardiac myocyte differentiation, apoptosis, fibrosis, and heart function (p=< 0.05). Transplanted embryonic stem cells overexpressing TIMP-1 significantly improved engraftment, cardiac myocyte differentiation, and heart function while reducing apoptosis and fibrosis (p<0.05) post-MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: